Novartis Ag (NVS) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Novartis Ag  (NYSE: NVS)


Novartis Ag's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Novartis Ag's ROI in the fourth quarter of 2025?
Novartis Ag achieved a return on average invested assets (ROI) of 22.42 % in its fourth quarter of 2025, this is above NVS's average return on investment of 11.54%.
Novartis Ags investments during the 12 months ending in the fourth quarter of 2025 are valued at $80 billion

ROI has improved compared to 20.54% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 101 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 0 to 777.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM 11.6 % 8.08 % 4.56 % -0.43 % -5.71 %
Y / Y Net Income Change TTM 18.48 % -11.81 % -11.81 % 2.23 % 2.23 %
Investment (TTM) in Millions 83,671 83,671 78,100 75,574 73,554
Return On Investment (TTM) 22.42 % 20.54 % 21.23 % 20.66 % 21.12 %
NVS's Overall Ranking # 777 # 0 # # #
Seq. Investment Change TTM 3.25 % 3.36 % 2.29 % 2.22 % -0 %
Seq. Net Income Change TTM 12.7 % 0 % 5.12 % 0 % -16.1 %
Net Income (TTM) in Millions 17,991 15,963 15,963 15,185 15,185

NVS Company Profile >> Back to NVS Roi Comparisons >> See Annual NVS Return On Investment



Return On Investment NVS's Ranking
Within: No.
Industry # 45
Sector # 102
Overall # 777

Return On Investment Statistics
High Average Low
18.26 %
11.54 %
5.03 %
(Dec 31 2021)   (Dec 31 2020)







Financial Statements
Novartis Ag's IV. Quarter Investments $ 83,671 Millions NVS's Balance sheet
Novartis Ag's IV. Quarter Income $ 13,967 Millions Quarterly NVS's Income Statement
NVS's Income by Division See NVS's Income by Division


NVS Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 83,671 73,554 73,555 88,797 101,587
Y / Y Investment Growth 13.75 % -0 % -17.16 % -12.59 % 7.25 %
Net Income in Millions 13,967 11,939 14,854 6,955 24,018
Y / Y Net Income Growth 16.99 % -19.62 % 113.57 % -71.04 % 197.58 %
Annual Return On Investment 16.69 % 16.23 % 20.19 % 7.83 % 23.64 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 16.69 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NVS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NVS's Competitors
Subscribers only: Roi for Novartis Ag's Suppliers
Subscribers only: Return On Investment for NVS's Customers

Other Ratios
NVS's Roa NVS's Inventory Turnover Ratio NVS's Growth Rates NVS's Dividend Statistics
NVS's Profitability Ratios NVS's Asset Turnover Ratio NVS's Dividend Growth
NVS's Roe NVS's Valuation Ratios NVS's Financial Strength Ratios NVS's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Aurinia Pharmaceuticals Inc   56.37 %
Pulmatrix Inc   53.09 %
Novavax inc   51.88 %
Q32 Bio Inc   50.33 %
Idexx Laboratories Inc  48.69 %
Theravance Biopharma inc   46.03 %
Elite Pharmaceuticals Inc   45.80 %
Enlivex Therapeutics Ltd  45.75 %
Gsk Plc  44.94 %
Galmed Pharmaceuticals Ltd   43.72 %
Abeona Therapeutics Inc   42.25 %
Alpha Tau Medical Ltd  42.04 %
Dariohealth Corp   41.31 %
Acadia Pharmaceuticals Inc   39.64 %
Medinotec Inc   37.45 %
Zevra Therapeutics Inc   36.78 %
Oramed Pharmaceuticals Inc  35.86 %
Ptc Therapeutics inc   35.12 %
Mettler toledo International Inc   34.74 %
Newgenivf Group Limited  32.05 %
Eli Lilly And Company  31.62 %
Indivior Pharmaceuticals Inc   31.00 %
Hutchmed china Limited  30.87 %
Medpace Holdings Inc   30.44 %
Adma Biologics Inc   28.75 %
Carlisle Companies Incorporated  27.24 %
Incyte Corporation  27.08 %
Vaxart Inc   26.63 %
Compugen Ltd  26.32 %
Arrowhead Pharmaceuticals Inc   25.56 %

Date modified: 2026-09-08T15:11:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.